A Phase II Study of CP-4055 plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia

Update Il y a 4 ans
Reference: EUCTR2008-008518-38

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

1. Estimate rate of complete remission (CR), including complete remission except for platelet count < 100 x 109/L (CRp) (CR + CRp rate) in patients with AML who have not attained blast clearance after the first course of a ara-C based remission-induction therapy.


Inclusion criteria

  • Acute Myeloid Leukaemia (AML)

Links